Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 190, Issue 1-2, Pages 170-176Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2007.08.009
Keywords
multiple sclerosis; interferon-beta; TNF-related apoptosis-inducing; ligand; CXC chemokine IP-10; monocyte chemoattractant protein-1; adverse effects; biological markers
Categories
Ask authors/readers for more resources
High serum levels of soluble TRAIL (sTRAIL) before or during the first year of Interferon-beta (IFN-beta) therapy were shown to predict an individual therapeutic response of patients with relapsing-remitting multiple sclerosis (RRMS). Here, we investigated whether sTRAIL plasma levels during long-term IFN-beta treatment correlate with future therapeutic response or adverse effects of treatment. Postinjection short-time bursts of sTRAIL were associated with flu-like symptoms and IP-10/CXCL 10 as well as MCP-1/CCL2 induction, and were detected after up to 6 years of continuous IFN-beta therapy. However, neither sTRAIL nor chemokine levels allowed prediction of one- and two-year clinical treatment response in 30 RRMS patients, prospectively followed by blinded investigators. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available